Molecular Cytogenetics Market Research, 2031
The global molecular cytogenetics market size was valued at $2.2 billion in 2021, and is projected to reach $5.2 billion by 2031, growing at a CAGR of 8.7% from 2022 to 2031. The molecular cytogenetics includes all the aspects of chromosome biology with a wide range of applications in disease diagnosis and chromosomal abnormalities. In order to distinguish between healthy cells and cancer-causing cells, molecular cytogenetics combines the fields of molecular biology and cytogenetics. It mainly includes a large set of the techniques that operate either with the entire genome or with specific targeted DNA sequences that can also be used as a diagnostic tool for congenital syndromes in which the underlying genetic causes of the disease are unknown.
According to the Centers for Disease Control and Prevention (CDC), in the U.S. in 2019, 1,752,735 new cancer cases were reported and for every 100,000 people, 439 new cancer cases were reported. Thus, rise in number of genetic related disorders such as cancer and tumors, highlights the need for the appropriate diagnosis procedure, thus propelling the growth of molecular cytogenetics market size. Also, usage of molecular cytogenetic products in clinical and research laboratories, academic research centers, pharmaceutical and biotechnology companies has increased as a result of high prevalence of diseases, significant economic burden of genetic abnormalities and cancer, and rise in healthcare expenditure.
Furthermore, with the increasing prevalence of cancers and genetic diseases, the demand for molecular cytogenetics is expected to register significant rise during the molecular cytogenetics market forecast period. International Online Medical Council (IOMC), states that around 1 in 50 people are affected by a known single-gene disorder, while around 1 in 263 are affected by a chromosomal disorder and around 65% of people have some kind of health problem as a result of congenital genetic mutations. Thus, this shows the need for the diagnosis procedures for the genetic disorders, which further causes the molecular cytogenetics market growth. However, high cost of treatment and lack of awareness about the emerging diagnostic technologies in molecular cytogenetics can cause hindrance to the growth of the market.
Rise in funding for research and clinical diagnosis, untapped emerging markets in Asia and transition from fish to array-based techniques are the lucrative opportunities for the growth of the market. In addition, acquisitions and collaborations by the key market players will further cause the expansion of the market. For instance, Danaher Company acquired fourteen companies in all four of its platforms along with the Cepheid, Integrated DNA Technologies, AVT, and Pall were their major acquisitions and the largest acquisition, Aldevron joined its life sciences segment providing a great advancement to the genomic medicine.
Impact of COVID-19 on Molecular Cytogenetics Market
The COVID-19 pandemic have proved to be an incomparable global public health emergency that has affected almost every industry, and the effects are expected to impact every industry growth during the forecast period. Several changes in consumer demand and behavior, buying habits, supply chain redirection, and significant government initiatives have been seen around the globe. The COVID-19 pandemic has changed the nutrition pattern, other substance use and other health-related behaviors of the population. In addition, with COVID-19 spreading across the world, hospitalization rates declined dramatically. There were several reports of many hospitals operating at less than 50% capacity to curtail noncritical medical services and elective surgeries. Hospitals are even less likely to conduct molecular cytogenetics tests. Therefore, COVID-19 is expected to have a significant impact on the molecular cytogenetics market.
The molecular cytogenetics market is segmented into Product, Technique, Application and End User.
The global molecular cytogenetics industry is segmented on the basis of product, technique, application, end user and region. On the basis of product, the market is categorized into instruments, consumables, and software & services. On the basis of technique, the market is segmented into comparative genomic hybridization, fluorescence in situ hybridization and others. Further, the comparative genomic hybridization segment is divided into array-based comparative genomic hybridization and standard comparative genomic hybridization. By application, it is divided into genetic disorders, cancer, personalized medicine and others. By end user, it is segmented into clinical & research laboratories, pharmaceutical & biotechnology companies and others (academic research institutes, CRO). Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
By product, the market is segmented into instruments, consumables, and software & services. The consumables segment generated maximum revenue in 2021. Moreover, the software and services segment is expected to expand at a higher CAGR during the forecast period owing to increase in incidence of genetic disorders and cancer, and increase in use of molecular pathology in disease diagnosis, disease prevention, and treatment using the molecular cytogenetics. However, developments in molecular cytogenetics are estimated to boost the segment during the forecast period.
Depending on the technique, the market is segmented into comparative genomic hybridization, fluorescence in situ hybridization and others. The comparative genomic hybridization holds a dominant position in the global molecular cytogenetics market in 2021, due to increase in laboratory automation which increases areas of application of comparative genomic hybridization in molecular cytogenetics and is also expected to grow at the fastest rate of CAGR during the forecast period.
Depending on the application, the market is divided into genetic disorders, cancer, personalized medicine and others. The genetic disorders segment dominated the market in 2021 due to prevalence of the factors causing genetic related disorders, whereas the personalized medicines segment is expected to grow with a highest CAGR.
Depending on end user, the market is divided into hospitals, diagnostic centers and others. The clinical and research laboratories segment dominated the market in 2021 and is expected to grow with highest CAGR, owing to surge in demand for advanced and precise diagnostic tools by pathologist and researchers in the academic research institutes.
Region wise, North America acquired a major molecular cytogenetics market share, owing to the presence of key players, rising government initiatives, well-developed healthcare infrastructure, and rising prevalence of chronic diseases. The region witnessed the highest growth of CAGR. However, Asia-Pacific is expected to witness the highest growth rate for the molecular cytogenetics market throughout the forecast period with a CAGR. The major factors that drive the growth of the molecular cytogenetics market in this region is the rising number of population, and investments by the public and private market players in this field. In addition, technological advancements, multiple applications, and increase in government initiatives to promote healthy lifestyle are driving the market growth.
The major companies profiled in this report include Abbott Laboratories, Agilent Technologies Inc., Applied Spectral Imaging, Cyto Test Inc., Danaher Corporation (Cephied), Empire Genomics, LLC., Genial Genetic Solutions Ltd., Illumina, Inc., Perkinelmer, Inc., Sema4 Holdings Corp., Sysmex Corporation (Oxford Gene Technology) and Thermo Fisher Scientific Inc. among others.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the molecular cytogenetics market analysis from 2021 to 2031 to identify the prevailing molecular cytogenetics market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the molecular cytogenetics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global molecular cytogenetics market trends, key players, market segments, application areas, and market growth strategies.
Molecular Cytogenetics Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 5.2 billion |
 Growth Rate | CAGR of 8.7% |
 Forecast period | 2021 - 2031 |
 Report Pages | 310 |
 By Product |
|
 By Technique |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Empire Genomics, LLC., Applied Spectral Imaging, Danaher Corporation (Cephied), PerkinElmer, Inc., Cyto Test Inc., Sysmex Corporation (Oxford Gene Technology), Sema4 Holdings Corp., Abbott Laboratories, Genial Genetic Solutions Ltd. |
Analyst Review
This section provides various opinions of top-level CXOs in the molecular cytogenetics market. The molecular cytogenetics market has piqued the interest of healthcare providers, diagnostic centers, and the patients. The technique offers several benefits which helps the researchers and pathologists to properly distinguish between the normal and cancer-causing cells. Also, there have been remarkable advancements in development of molecular cytogenetics to provide advanced options for cancer diagnosis and treatment. As the market is saturated and is growing at a steady rate in developed nations, Asia-Pacific and LAMEA are expected to offer high growth opportunities to key players in this market.
According to the perspectives of CXOs of leading companies in the market, significant advancements in the molecular cytogenetics with increase in clinically backed research, growing investments, funds, and grants, increase in incidence of target diseases, entry of new players, and growth in the awareness about the treatment options is projected to increase the molecular cytogenetics market globally. In addition, increase in incidence of genetic disorders and cancer, rise in prevalence of chronic diseases, increase in use molecular cytogenetics in clinical pathological testing, and growth in inclination toward targeted cancer treatment, are propelling the growth of the market.
number of populations, investments by the public and private market players in this field, technological advancements, and increase in government initiatives to promote healthy lifestyle are the upcoming trends of Molecular Cytogenetics Market.
Genetic disorder is the leading application of Molecular Cytogenetics Market.
North America is the largest regional market for Molecular Cytogenetics
Molecular Cytogenetics market is projected to reach $5,146.55 million by 2031, registering a CAGR of 8.7%.
The major companies profiled in this report include Abbott Laboratories, Agilent Technologies Inc., Applied Spectral Imaging, Cyto Test Inc., Danaher Corporation (Cephied), Empire Genomics, LLC., Genial Genetic Solutions Ltd., Illumina, Inc., Perkinelmer, Inc., Sema4 Holdings Corp., Sysmex Corporation (Oxford Gene Technology) and Thermo Fisher Scientific Inc. among others.
The base year is 2021 in Molecular Cytogenetics market.
Yes, the Molecular Cytogenetics market report provides PORTER Analysis.
Loading Table Of Content...
